How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
PARP Inhibitor Biomarkers Testing Product Market
- By Biomarker Type: BRCA1 Mutation Testing, BRCA2 Mutation Testing, Homologous Recombination Deficiency (HRD) Testing, PALB2 Mutation Testing, RAD51C/D Mutation Testing
- By Testing Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Microarray Analysis
- By Sample Type: Tumor Tissue Biopsy, Circulating Tumor DNA (ctDNA), Peripheral Blood, Formalin-Fixed Paraffin-Embedded (FFPE) Tissue, Fresh Frozen Tissue
- By End-User: Hospital Laboratories, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Contract Research Organizations (CROs)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - BRCA1 Mutation Testing leads By Biomarker Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 286 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the PARP Inhibitor Biomarkers Testing Product Market report
A complete, evidence-based study - 11 chapters and 120 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Biomarker Type 5
Testing Technology 5
Sample Type 5
End-User 5
Companies profiled
Myriad Genetics Inc.
Invitae Corporation
Foundation Medicine
Inc. (a subsidiary of Roche)
Guardant Health Inc.
Freenome Holdings Inc.
Natera Inc.
Caris Life Sciences
Tempus Labs Inc.
SomaLogic Inc.
Personalis Inc.
Q2 Solutions (a division of IQVIA)
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Myriad Genetics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Invitae Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Foundation Medicine
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Inc. (a subsidiary of Roche)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Guardant Health Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Freenome Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Natera Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Caris Life Sciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Tempus Labs Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →SomaLogic Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Personalis Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Q2 Solutions (a division of IQVIA)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Biocept Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →PathAI Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Oncocyte Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Genomic Health
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc. (a Exact Sciences Company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,798M by 2033 · 5.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- BRCA1 Mutation Testing41.1
- BRCA2 Mutation Testing8.7
- Homologous Recombination Deficiency (HRD) Testing23.2
- PALB2 Mutation Testing13.6
- RAD51C/D Mutation Testing13.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$612.8M → $918.6M · 5.2%
Europe$427.1M → $586.4M · 4.0%
Asia Pacific$390.0M → $534.2M · 4.0%
Latin America$241.4M → $370.5M · 5.5%
Middle East and Africa$185.7M → $258.6M · 4.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.202026
5.232027
5.232028
5.252029
5.252030
5.262031
5.282032
5.292033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Myriad Genetics Inc.22.5
- Invitae Corporation20.8
- Foundation Medicine6.0
- Inc. (a subsidiary of Roche)5.9
- Guardant Health Inc.10.2
- Freenome Holdings Inc.6.5
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Biomarker Type13.7%
Testing Technology32.0%
Sample Type25.8%
End-User28.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.4
- Europe22.0
- Asia Pacific20.0
- Latin America13.9
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Myriad Genetics Inc. | 76 | 74 | 96 | 77 | 84 | 80 | 81 |
| Invitae Corporation | 85 | 82 | 84 | 78 | 84 | 69 | 80 |
| Foundation Medicine | 87 | 71 | 68 | 87 | 64 | 87 | 77 |
| Inc. (a subsidiary of Roche) | 77 | 63 | 59 | 78 | 73 | 71 | 70 |
| Guardant Health Inc. | 72 | 63 | 60 | 66 | 63 | 70 | 66 |
| Freenome Holdings Inc. | 64 | 61 | 52 | 57 | 69 | 66 | 62 |
| Natera Inc. | 54 | 52 | 54 | 41 | 62 | 55 | 53 |
| Caris Life Sciences | 56 | 42 | 60 | 56 | 38 | 48 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Myriad Genetics Inc.
- Invitae Corporation
- Foundation Medicine
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Myriad Genetics Inc. | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Invitae Corporation | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Foundation Medicine | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Inc. (a subsidiary of Roche) | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Guardant Health Inc. | ◐ | ◐ | ◐ | ◐ | − | − |
| Freenome Holdings Inc. | ◐ | − | − | ◐ | ◐ | ◐ |
| Natera Inc. | − | − | − | ◐ | ◐ | − |
| Caris Life Sciences | ◐ | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Myriad Genetics Inc.81
2Invitae Corporation80
3Foundation Medicine77
4Inc. (a subsidiary of Roche)70
5Guardant Health Inc.66
6Freenome Holdings Inc.62
7Natera Inc.53
8Caris Life Sciences50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Myriad Genetics Inc.Invitae Corporation
Challenger2
Strong scale, closing on the leaders.
Foundation MedicineInc. (a subsidiary of Roche)
Contender2
Focused players with pockets of strength.
Guardant Health Inc.Freenome Holdings Inc.
Niche2
Specialists in a single segment or region.
Natera Inc.Caris Life Sciences
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Biomarker Type in North America, then scale across PARP Inhibitor Biomarkers Testing Product Market — a $144M beachhead inside a $2.37B market.
Beachhead (SOM)$144Mobtainable near-term
Serviceable (SAM)$944Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
BRCA1 Mutation Testing
Best fit — highest urgency & budget in Biomarker Type.
Economic buyer81 fit
BRCA2 Mutation Testing
Strong fit — clear ROI and a fast path to value.
End user65 fit
Homologous Recombination Deficiency (HRD) Testing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Biomarker Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Testing Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Sample Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Biomarker Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win PARP Inhibitor Biomarkers Testing Product Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified21%
Evaluation14%
Closed-won7%
$14.7KCAC
$61KLTV
4.2:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
PARP Inhibitor Biomarkers Testing Product Market is a high-growth opportunity — $9.28B by 2033, compounding at 10.4%.
TAM · 2025$4.20Btoday
TAM · 2033$9.28Bforecast
CAGR10.4%2027–2033
Cumulative$58.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.28BTotal addressable market
SAM$3.25BServiceable available market
SOM$568MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.4% CAGR
Demand compounds through 2033, outpacing GDP across Biomarker Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Biomarker Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.28BLarge & growingTAM by 2033 at 10.4% CAGR
$3.25BServiceable nowreachable with today’s model
$568MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.24BBear6.8% CAGR
$9.28BBase10.4% CAGR
$11.9BBull13.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Testing Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
PARP Inhibitor Biomarkers Testing Product Market — a $6.85B market by 2033. Plan: grow share from 7.9% to 14.3%.
Market size · 2033$6.85Btotal addressable
Market CAGR9.1%2027–2033
Target share14.3%from 7.9% today
Revenue ambition$979Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 14.3% | Ahead |
| Revenue | $498M | $979M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 28.8% | 44.8% | On track |
| Customer retention | 91.5% | 94.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Biomarker Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Testing Technology capability
A defensible second engine — invest in Testing Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Biomarker Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Testing Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $128M capacity & capability investment
- Greenlight bolt-on M&A in Testing Technology
- Authorise North America expansion plan
- Fund R&D program for Biomarker Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the PARP Inhibitor Biomarkers Testing Product Market conversation — a $8.08B market you can size, segment and defend in minutes.
Market size · 2033$8.08Btotal opportunity
Growth11.2%CAGR to 2033
Addressable buyers1,505+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Biomarker Type
Goal Grow share in Biomarker Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 2 mopayback period
$93K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Myriad Genetics Inc.Invitae CorporationFoundation MedicineInc. (a subsidiary of Roche)Guardant Health Inc.Freenome Holdings Inc.Natera Inc.Caris Life Sciences+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your PARP Inhibitor Biomarkers Testing Product Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
PARP Inhibitor Biomarkers Testing Product Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →PARP Inhibitor Biomarkers Service Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportPARP1 Antibody Market
Market size, share, segmentation and regional forecast.
$766M market · 2025 base year
View reportParoxysmal Nocturnal Hemoglobinuria Drug Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportParoxetine Mesylate Market
Market size, share, segmentation and regional forecast.
$461M market · 2025 base year
View reportParoxetine Hydrochloride Tablet Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportParoxetine Hydrochloride Hemihydrate Market
Market size, share, segmentation and regional forecast.
$615M market · 2025 base year
View reportParomomycin Sulfate Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportParomomycin Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportParkinson Treatment Drug Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportParenteral Nutrition Solutions Market
Market size, share, segmentation and regional forecast.
$765M market · 2025 base year
View reportParenteral Nutrition Medicament Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportParenteral Nutrition Infusion Bag Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.